ABL001A
Total Payments
$1.3M
Transactions
70
Doctors
2
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $329,980 | 21 | 1 |
| 2019 | $627,025 | 19 | 0 |
| 2018 | $324,453 | 18 | 0 |
| 2017 | $60,448 | 12 | 1 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.3M | 70 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A PHASE 3 MULTI CENTER OPEN LABEL RANDOMIZED STUDY OF ORAL ABL001 VERSUS BOSUTINIB IN PATIENTS WITH CHRONIC MYELOGENOUS LEUKEMIA IN CHRONIC PHASE CML CP PREVIOUSLY TREATED WITH 2 OR MORE TYROSINE KINASE INHIBITORS | Novartis Pharmaceuticals Corporation | $1.2M | 0 |
| A PHASE I OPEN LABEL MULTI CENTER SINGLE DOSE PARALLEL GROUP STUFY TO EVALUATE THE PHARMACOKINETICS OF ABL001 IN HEALTHY SUBJECTS WITH NORMAL HEPATIC FUNCTION AND SUBJECTS WITH IMPAIRED HEPATIC FUNCTIONS | Novartis Pharmaceuticals Corporation | $91,954 | 0 |
| PHASE 2 STUDY OF DUAL TARGETING OF BCR-ABL1 BY ADDING THE ALLOSTERIC INHIBITOR ABL001 IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA (CML) AND MINIMAL RESIDUAL DISEASE WHILE ON THERAPY WITH TYROSINE KINASE INHIBITORS.??? | Novartis Pharmaceuticals Corporation | $39,375 | 0 |
| RESEARCH RELATED PUBLICATIONS SUPPORT | Novartis Pharmaceuticals Corporation | $1,407 | 1 |
| HUMAN ADME ABL001 | Novartis Pharmaceuticals Corporation | $825.35 | 0 |
| RESEARCH RELATED PUBLICATION SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $286.50 | 1 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $1.3M
- Total Doctors 2
- Transactions 70
About ABL001A
ABL001A is a drug associated with $1.3M in payments to 2 healthcare providers, recorded across 70 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2017 to 2020. In 2020, $329,980 was paid across 21 transactions to 1 doctors.
The most common payment nature for ABL001A is "Unspecified" ($1.3M, 100.0% of total).
ABL001A is associated with 6 research studies, including "A PHASE 3 MULTI CENTER OPEN LABEL RANDOMIZED STUDY OF ORAL ABL001 VERSUS BOSUTINIB IN PATIENTS WITH CHRONIC MYELOGENOUS LEUKEMIA IN CHRONIC PHASE CML CP PREVIOUSLY TREATED WITH 2 OR MORE TYROSINE KINASE INHIBITORS" ($1.2M).